These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 31314617)

  • 1. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects.
    Poorebrahim M; Sadeghi S; Fakhr E; Abazari MF; Poortahmasebi V; Kheirollahi A; Askari H; Rajabzadeh A; Rastegarpanah M; Linē A; Cid-Arregui A
    Crit Rev Clin Lab Sci; 2019 Sep; 56(6):393-419. PubMed ID: 31314617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized Production of Lentiviral Vectors for CAR-T Cell.
    Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
    Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in CAR-T cell engineering.
    Huang R; Li X; He Y; Zhu W; Gao L; Liu Y; Gao L; Wen Q; Zhong JF; Zhang C; Zhang X
    J Hematol Oncol; 2020 Jul; 13(1):86. PubMed ID: 32616000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.
    Labbé RP; Vessillier S; Rafiq QA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.
    Yuan W; Chen J; Cao Y; Yang L; Shen L; Bian Q; Bin S; Li P; Cao J; Fang H; Gu H; Li H
    J Gene Med; 2018 Jul; 20(7-8):e3027. PubMed ID: 29851200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of CAR-T cells using lentiviral vectors.
    Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
    Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors.
    Morgan MA; Schambach A
    Hum Gene Ther; 2018 Oct; 29(10):1083-1097. PubMed ID: 30156435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
    Ueda T; Kaneko S
    Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.
    Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H
    J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates on CAR T-cell therapy in B-cell malignancies.
    Jacoby E; Shahani SA; Shah NN
    Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.